Document is current
Any future updates will be listed below
-
Authors
Saatci, Ozge https://orcid.org/0000-0002-0124-044X
Alam, Rashedul
Huynh-Dam, Kim-Tuyen
Isik, Aynur
Uner, Meral https://orcid.org/0000-0001-9927-1246
Belder, Nevin https://orcid.org/0000-0001-9353-9387
Ersan, Pelin Gulizar https://orcid.org/0000-0003-3637-4090
Tokat, Unal Metin https://orcid.org/0000-0003-0026-368X
Ulukan, Burge https://orcid.org/0000-0002-1101-8834
Cetin, Metin
Calisir, Kubra https://orcid.org/0000-0002-6204-1022
Gedik, Mustafa Emre
Bal, Hilal https://orcid.org/0000-0003-1668-6070
Sener Sahin, Ozlem
Riazalhosseini, Yasser
Thieffry, Denis
Gautheret, Daniel
Ogretmen, Besim https://orcid.org/0000-0002-1019-5660
Aksoy, Sercan https://orcid.org/0000-0003-4984-1049
Uner, Aysegul
Akyol, Aytekin
Sahin, Ozgur https://orcid.org/0000-0002-8033-7089
-
Funding
Funding for this research was provided by:
American Cancer Society (RSG-19-194-01-CSM)
Foundation for the National Institutes of Health (R01CA251374, R01CA267101, C06 RR015455, P30 GM103339)
Susan G. Komen (GTDR17500160)
TUBITAK-CNRS Bilateral Grant
- License Information
-
More Information
Article History
Received: 21 November 2023
Revised: 5 June 2024
Accepted: 6 June 2024
First Online: 15 June 2024
Competing interests
: O.S. is the co-founder of OncoCube Therapeutics LLC, the founder and president of LoxiGen, Inc., and the scientific advisory board member of A2A Pharmaceuticals. The other authors declare no potential competing interests.
: The study was approved by the Non‐Interventional Clinical Research Ethics Committee of Hacettepe University (approval no: 2020/02-40). Informed consent was obtained from all patients.
